Article Information
History
- May 9, 2024.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Niklas Worm Andersson, doctoral student1,*,
- Emilia Myrup Thiesson, statistician1,
- Nicklas Pihlström, statistician2,3,
- Jori Perälä, statistician4,
- Kristýna Faksová, junior epidemiologist1,
- Mie Agermose Gram, junior epidemiologist1,
- Eero Poukka, doctoral student4,5,
- Tuija Leino, senior epidemiologist4,
- Rickard Ljung, professor2,3 and
- Anders Hviid, head of department, professor1,6
- 1Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark
- 2Division of Use and Information, Swedish Medical Products Agency, Uppsala, Sweden
- 3Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
- 4Infectious Disease Control and Vaccinations Unit, Department of Health Security, Finnish Institute for Health and Welfare, Helsinki, Finland
- 5Department of Public Health, Faculty of Medicine, University of Helsinki, Helsinki, Finland
- 6Pharmacovigilance Research Center, Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
- ↵*Corresponding author: Niklas Worm Andersson, Department of Epidemiology Research, Statens Serum Institut, Artillerivej 5, 2300 Copenhagen S, Denmark, Email: nian{at}ssi.dk, telephone: +45 3268 3159, Orcid-id: 0000-0001-7622-6303
Posted May 09, 2024.
Comparative effectiveness of the monovalent XBB.1.5-containing covid-19 mRNA vaccine across three Nordic countries
